Trials / Completed
CompletedNCT02513719
XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE PRIME SV Japan PMS)
XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 312 (actual)
- Sponsor
- Abbott Medical Devices · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to evaluate the safety and efficacy of XIENCE PRIME SV in real world practice in Japanese hospitals.
Detailed description
Based on Good Post-marketing Study Practice (GPSP) regulation, general patient population with ischemic heart disease who are eligible for treatment with XIENCE PRIME SV Everolimus Eluting Stent will be registered, with no particular inclusion/exclusion criteria, and may be eligible for angiographic follow-up at eight months and clinical follow-up at one year.
Conditions
- Ischemic Heart Disease
- Angina Pectoris
- Coronary Artery Disease
- Coronary Artery Occlusion
- Myocardial Ischemia
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | XIENCE PRIME SV Everolimus Eluting Coronary Stent | Patients receiving XIENCE PRIME SV Everolimus Eluting Stent |
Timeline
- Start date
- 2013-05-13
- Primary completion
- 2019-09-01
- Completion
- 2019-09-01
- First posted
- 2015-08-03
- Last updated
- 2024-04-04
- Results posted
- 2019-07-22
Locations
33 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02513719. Inclusion in this directory is not an endorsement.